CX3CL1 and ovarian serous carcinoma: It also has been found that a specific ligand of the CX3CR1 receptor, also known as fractalkine, or CX3CL1, is expressed by the ovarian carcinoma cells themselves, and a soluble form of this chemokine is present in the malignant ascites of serous ovarian carcinoma patients [33,34].